公开(公告)号：US20240325550A1

公开(公告)日：2024-10-03

申请号：US18618258

申请日：2024-03-27

Applicant: KIST (Korea Institute of Science and Technology) ,  K2B Therapeutics, Inc.

Inventor： HoWon J. Kim ,  In-San Kim ,  Jay S. Kim ,  Sun Hwa Kim ,  Ick Chan Kwon ,  Jong Won Lee ,  Yoo Soo Yang ,  Hong Yeol Yoon

IPC: A61K47/64 ,  A61P35/00 ,  C12N15/113

CPC classification number: A61K47/64 ,  A61P35/00 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/141

Abstract: Therapeutic compounds for inhibiting and reducing the expression of cell surface proteins and methods for treating cancer, inflammation, and diabetes using the therapeutic compounds.

公开(公告)号：US10905774B2

公开(公告)日：2021-02-02

申请号：US16247937

申请日：2019-01-15

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Gi Hoon Nam ,  Eun Jung Lee ,  Yoo Soo Yang ,  Cherl Hyun Jeong ,  In-San Kim ,  Kwangmeyung Kim

IPC: A61K39/00 ,  A61K47/00 ,  A61K9/14 ,  A61K39/12 ,  A61K47/69 ,  A61K31/704 ,  C07K14/79 ,  C07K14/47 ,  A61K31/69 ,  A61K9/51 ,  A61K39/395 ,  A61P35/00 ,  A61K31/337 ,  B82Y5/00 ,  B82Y40/00 ,  C07K14/005 ,  C07K14/705 ,  C07K14/785 ,  C07K16/28

Abstract: The present invention relates to a novel recombinant nanocage and use thereof wherein the nanocage is formed by self-assembly of a fusion protein including a phagocytosis enhancing protein and a self-assembling protein, and to a protein nanocage complex in which an immunogenic cell death inducer is loaded in the nanocage as an active ingredient.

公开(公告)号：US20190307794A1

公开(公告)日：2019-10-10

申请号：US16379523

申请日：2019-04-09

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Yeon-Sun HONG ,  Hyo Suk Kim ,  Yoo Soo Yang ,  Sun Hwa Kim ,  In-San Kim ,  Ick Chan Kwon

IPC: A61K35/15 ,  C12N5/0786 ,  C12N5/0784 ,  C12N5/0775 ,  A61K9/127 ,  C12N5/00

Abstract: The present invention relates to a method of inducing trans-differentiating a first type of immune cell into a second type of immune cell comprising: isolating exosomes from the second type of immune cell that has undergone differentiation, and treating the first type of immune cell or a cell population including the first type of immune cell with the isolated exosomes in vitro.